AU2002223106A1 - Stimulation of thymus for vaccination development - Google Patents

Stimulation of thymus for vaccination development

Info

Publication number: AU2002223106A1
Authority: AU; Australia
Prior art keywords: cells; thymus; ofthe; cell; patient
Prior art date: 2000-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002223106A

Other languages

English (en)

Inventor

Richard Boyd

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Norwood Immunology Ltd

Original Assignee

Norwood Immunology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-13

Filing date

2001-10-12

Publication date

2002-04-22

2000-10-13 Priority claimed from AUPR0745A external-priority patent/AUPR074500A0/en

2001-01-05 Priority claimed from US09/755,965 external-priority patent/US20010046486A1/en

2001-10-12 Application filed by Norwood Immunology Ltd filed Critical Norwood Immunology Ltd

2002-04-22 Publication of AU2002223106A1 publication Critical patent/AU2002223106A1/en

2004-10-07 Assigned to NORWOOD IMMUNOLOGY LTD reassignment NORWOOD IMMUNOLOGY LTD Request for Assignment Assignors: MONASH UNIVERSITY

Status Abandoned legal-status Critical Current

Links

210000001541 thymus gland Anatomy 0.000 title claims description 117
238000002255 vaccination Methods 0.000 title claims description 14
230000000638 stimulation Effects 0.000 title description 6
238000011161 development Methods 0.000 title description 4
238000000034 method Methods 0.000 claims description 48
239000003163 gonadal steroid hormone Substances 0.000 claims description 39
239000000556 agonist Substances 0.000 claims description 35
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 29
210000000987 immune system Anatomy 0.000 claims description 18
230000004044 response Effects 0.000 claims description 18
230000011664 signaling Effects 0.000 claims description 14
230000001404 mediated effect Effects 0.000 claims description 13
229960005486 vaccine Drugs 0.000 claims description 13
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 9
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 9
230000007420 reactivation Effects 0.000 claims description 7
230000002294 pubertal effect Effects 0.000 claims description 6
108010000817 Leuprolide Proteins 0.000 claims description 5
210000002149 gonad Anatomy 0.000 claims description 5
108010069236 Goserelin Proteins 0.000 claims description 4
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 4
229960004338 leuprorelin Drugs 0.000 claims description 4
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 3
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 3
108700025485 deslorelin Proteins 0.000 claims description 3
229960005408 deslorelin Drugs 0.000 claims description 3
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 3
YGGIRYYNWQICCP-LDRBRYNMSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydrox Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 YGGIRYYNWQICCP-LDRBRYNMSA-N 0.000 claims description 2
HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 2
108010037003 Buserelin Proteins 0.000 claims description 2
-1 Dioxalan derivatives Chemical compound 0.000 claims description 2
108010021717 Nafarelin Proteins 0.000 claims description 2
230000000735 allogeneic effect Effects 0.000 claims description 2
229960002719 buserelin Drugs 0.000 claims description 2
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
229960002913 goserelin Drugs 0.000 claims description 2
108700020746 histrelin Proteins 0.000 claims description 2
229960002193 histrelin Drugs 0.000 claims description 2
HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 2
229960003822 lutrelin Drugs 0.000 claims description 2
108700025096 meterelin Proteins 0.000 claims description 2
229960002333 nafarelin Drugs 0.000 claims description 2
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
229960004824 triptorelin Drugs 0.000 claims description 2
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 2
102100024028 Progonadoliberin-1 Human genes 0.000 claims 2
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 2
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 2
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 1
210000004027 cell Anatomy 0.000 description 121
210000001744 T-lymphocyte Anatomy 0.000 description 119
241000699670 Mus sp. Species 0.000 description 84
238000011282 treatment Methods 0.000 description 50
210000003491 skin Anatomy 0.000 description 40
239000000427 antigen Substances 0.000 description 39
108091007433 antigens Proteins 0.000 description 39
102000036639 antigens Human genes 0.000 description 39
235000021251 pulses Nutrition 0.000 description 39
230000007423 decrease Effects 0.000 description 35
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 34
230000001965 increasing effect Effects 0.000 description 34
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 29
230000002992 thymic effect Effects 0.000 description 29
230000001052 transient effect Effects 0.000 description 27
210000001165 lymph node Anatomy 0.000 description 26
210000004443 dendritic cell Anatomy 0.000 description 24
230000000694 effects Effects 0.000 description 23
210000000981 epithelium Anatomy 0.000 description 22
230000035755 proliferation Effects 0.000 description 21
230000008859 change Effects 0.000 description 20
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
238000004519 manufacturing process Methods 0.000 description 19
210000000434 stratum corneum Anatomy 0.000 description 19
239000013077 target material Substances 0.000 description 18
241001465754 Metazoa Species 0.000 description 17
150000001875 compounds Chemical class 0.000 description 17
239000000203 mixture Substances 0.000 description 16
210000000952 spleen Anatomy 0.000 description 15
210000003719 b-lymphocyte Anatomy 0.000 description 14
230000008878 coupling Effects 0.000 description 14
238000010168 coupling process Methods 0.000 description 14
238000005859 coupling reaction Methods 0.000 description 14
239000000126 substance Substances 0.000 description 14
238000002679 ablation Methods 0.000 description 13
230000004075 alteration Effects 0.000 description 13
230000003247 decreasing effect Effects 0.000 description 13
230000014509 gene expression Effects 0.000 description 13
230000035882 stress Effects 0.000 description 13
238000004458 analytical method Methods 0.000 description 12
210000002919 epithelial cell Anatomy 0.000 description 12
230000002093 peripheral effect Effects 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
238000012360 testing method Methods 0.000 description 12
108091008874 T cell receptors Proteins 0.000 description 11
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
238000009472 formulation Methods 0.000 description 11
210000001185 bone marrow Anatomy 0.000 description 10
230000028993 immune response Effects 0.000 description 10
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 9
108700018351 Major Histocompatibility Complex Proteins 0.000 description 9
230000001605 fetal effect Effects 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
230000002062 proliferating effect Effects 0.000 description 9
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 8
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 8
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 8
210000000612 antigen-presenting cell Anatomy 0.000 description 8
229950004398 broxuridine Drugs 0.000 description 8
229960004397 cyclophosphamide Drugs 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
230000003287 optical effect Effects 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
230000008929 regeneration Effects 0.000 description 8
238000011069 regeneration method Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
241000700588 Human alphaherpesvirus 1 Species 0.000 description 7
102000008238 LHRH Receptors Human genes 0.000 description 7
108010021290 LHRH Receptors Proteins 0.000 description 7
210000000662 T-lymphocyte subset Anatomy 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
230000009021 linear effect Effects 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
210000000066 myeloid cell Anatomy 0.000 description 7
230000009467 reduction Effects 0.000 description 7
150000003431 steroids Chemical class 0.000 description 7
206010003694 Atrophy Diseases 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
238000010317 ablation therapy Methods 0.000 description 6
230000037444 atrophy Effects 0.000 description 6
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
210000005259 peripheral blood Anatomy 0.000 description 6
239000011886 peripheral blood Substances 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010060862 Prostate cancer Diseases 0.000 description 5
208000000236 Prostatic Neoplasms Diseases 0.000 description 5
210000004241 Th2 cell Anatomy 0.000 description 5
238000001514 detection method Methods 0.000 description 5
210000005081 epithelial layer Anatomy 0.000 description 5
239000002434 gonadorelin derivative Substances 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000035800 maturation Effects 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
239000012780 transparent material Substances 0.000 description 5
102100032912 CD44 antigen Human genes 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
239000004793 Polystyrene Substances 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
210000004544 dc2 Anatomy 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
239000007943 implant Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000035699 permeability Effects 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
229920002223 polystyrene Polymers 0.000 description 4
230000005855 radiation Effects 0.000 description 4
238000010186 staining Methods 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
230000001360 synchronised effect Effects 0.000 description 4
230000002123 temporal effect Effects 0.000 description 4
241000124008 Mammalia Species 0.000 description 3
102000007079 Peptide Fragments Human genes 0.000 description 3
108010033276 Peptide Fragments Proteins 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000032683 aging Effects 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
230000004957 immunoregulator effect Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
239000004033 plastic Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
210000002536 stromal cell Anatomy 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
230000002792 vascular Effects 0.000 description 3
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
206010003497 Asphyxia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
102400000739 Corticotropin Human genes 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
108700012941 GNRH1 Proteins 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
208000037952 HSV-1 infection Diseases 0.000 description 2
229910052689 Holmium Inorganic materials 0.000 description 2
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
102000003812 Interleukin-15 Human genes 0.000 description 2
108090000172 Interleukin-15 Proteins 0.000 description 2
102000000704 Interleukin-7 Human genes 0.000 description 2
108010002586 Interleukin-7 Proteins 0.000 description 2
108010076876 Keratins Proteins 0.000 description 2
102000011782 Keratins Human genes 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010085012 Steroid Receptors Proteins 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
108010023617 abarelix Proteins 0.000 description 2
AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 2
229960002184 abarelix Drugs 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
239000012829 chemotherapy agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000002716 delivery method Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000005684 electric field Effects 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 2
230000003284 homeostatic effect Effects 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000002706 hydrostatic effect Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940100994 interleukin-7 Drugs 0.000 description 2
229940039412 ketalar Drugs 0.000 description 2
229960004184 ketamine hydrochloride Drugs 0.000 description 2
238000002372 labelling Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000000608 laser ablation Methods 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000009022 nonlinear effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
230000008823 permeabilization Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000010453 quartz Substances 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
229940069575 rompun Drugs 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
102000005969 steroid hormone receptors Human genes 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
229940033942 zoladex Drugs 0.000 description 2
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
229910052691 Erbium Inorganic materials 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
102400000932 Gonadoliberin-1 Human genes 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
241000289419 Metatheria Species 0.000 description 1
LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
NGCGMRBZPXEPOZ-HBBGHHHDSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)- Chemical compound CC(O)=O.C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NGCGMRBZPXEPOZ-HBBGHHHDSA-N 0.000 description 1
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
230000007175 bidirectional communication Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000003990 capacitor Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
239000008004 cell lysis buffer Substances 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
108700008462 cetrorelix Proteins 0.000 description 1
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
229960003230 cetrorelix Drugs 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
229940002533 cystorelin Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000009547 development abnormality Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229960001442 gonadorelin Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940087857 lupron Drugs 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
230000008747 mitogenic response Effects 0.000 description 1
229940029345 neupogen Drugs 0.000 description 1
210000000607 neurosecretory system Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
150000002910 rare earth metals Chemical class 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
239000010979 ruby Substances 0.000 description 1
229910001750 ruby Inorganic materials 0.000 description 1
239000000523 sample Substances 0.000 description 1
229910052594 sapphire Inorganic materials 0.000 description 1
239000010980 sapphire Substances 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
108010066312 streptavidin-tricolor Proteins 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Reproductive Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Virology (AREA)
Rheumatology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2002223106A 2000-10-13 2001-10-12 Stimulation of thymus for vaccination development Abandoned AU2002223106A1 (en)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US79530200A	2000-10-13	2000-10-13
US79528600A	2000-10-13	2000-10-13
AUPR0745A AUPR074500A0 (en)	2000-10-13	2000-10-13	Treatment of t cell disorders
AUPR0745		2000-10-13
US09/795286		2000-10-13
US09/795302		2000-10-13
US09/755965		2001-01-05
US09/755,965 US20010046486A1 (en)	2000-04-17	2001-01-05	Stimulation of thymus for vaccination development
US09/965,394 US20020086000A1 (en)	1999-04-15	2001-09-26	Stimulation of thymus for vaccination development
US09/965394		2001-09-26
PCT/IB2001/002350 WO2002030320A2 (fr)	2000-10-13	2001-10-12	Stimulation du thymus pour ameliorer une vaccination

Publications (1)

Publication Number	Publication Date
AU2002223106A1 true AU2002223106A1 (en)	2002-04-22

Family

ID=27507496

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002223106A Abandoned AU2002223106A1 (en)	2000-10-13	2001-10-12	Stimulation of thymus for vaccination development

Country Status (11)

Country	Link
US (1)	US20020086000A1 (fr)
EP (1)	EP1355653A4 (fr)
JP (1)	JP2004517051A (fr)
CN (1)	CN1505522A (fr)
AP (1)	AP2003002797A0 (fr)
AU (1)	AU2002223106A1 (fr)
BR (1)	BR0114641A (fr)
CA (1)	CA2462027A1 (fr)
IL (1)	IL155410A0 (fr)
NZ (1)	NZ525825A (fr)
WO (1)	WO2002030320A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20060022232A (ko) *	2003-04-18	2006-03-09	노르우드 이뮤놀러지 리미티드	흉선 재활성화 이전에 수행되는 질병 예방법 및 면역방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1037918B1 (fr) *	1997-12-11	2009-03-04	University Of Maryland Biotechnology Institute	Compositions pour ameliorer l'efficacite d'un vaccin utilisant des chemokines
AUPP977899A0 (en) *	1999-04-15	1999-05-13	Monash University	Improvement of t cell mediated immunity
US20010046486A1 (en) *	2000-04-17	2001-11-29	Boyd Richard L.	Stimulation of thymus for vaccination development

2001
- 2001-09-26 US US09/965,394 patent/US20020086000A1/en not_active Abandoned
- 2001-10-12 BR BR0114641-6A patent/BR0114641A/pt not_active Application Discontinuation
- 2001-10-12 IL IL15541001A patent/IL155410A0/xx unknown
- 2001-10-12 AU AU2002223106A patent/AU2002223106A1/en not_active Abandoned
- 2001-10-12 AP APAP/P/2003/002797A patent/AP2003002797A0/en unknown
- 2001-10-12 NZ NZ525825A patent/NZ525825A/en unknown
- 2001-10-12 CA CA002462027A patent/CA2462027A1/fr not_active Abandoned
- 2001-10-12 JP JP2002533768A patent/JP2004517051A/ja active Pending
- 2001-10-12 CN CNA018202918A patent/CN1505522A/zh active Pending
- 2001-10-12 EP EP01986586A patent/EP1355653A4/fr not_active Withdrawn
- 2001-10-12 WO PCT/IB2001/002350 patent/WO2002030320A2/fr not_active Ceased

Also Published As

Publication number	Publication date
EP1355653A2 (fr)	2003-10-29
AP2003002797A0 (en)	2003-06-30
CA2462027A1 (fr)	2002-04-18
JP2004517051A (ja)	2004-06-10
WO2002030320A2 (fr)	2002-04-18
IL155410A0 (en)	2003-11-23
CN1505522A (zh)	2004-06-16
BR0114641A (pt)	2004-01-20
WO2002030320A3 (fr)	2002-06-20
NZ525825A (en)	2005-05-27
EP1355653A4 (fr)	2006-05-31
US20020086000A1 (en)	2002-07-04

Publication	Publication Date	Title
CA2462758A1 (fr)	2002-04-18	Indicateur de diagnostic de la fonction thymique
EP1363703A2 (fr)	2003-11-26	Prevention de maladies par reactivation du thymus
US20020136704A1 (en)	2002-09-26	Diagnostic indicator of thymic function
US20020119128A1 (en)	2002-08-29	Graft acceptance through manipulation of thymic regeneration
WO2002031110A2 (fr)	2002-04-18	Therapie genique aux cellules souches hematopoietiques
AU2002216323B2 (en)	2007-11-15	Disease prevention by reactivation of the thymus
AU2002225245B2 (en)	2008-01-31	Improvement of graft acceptance through manipulation of thymic regeneration
WO2002030257A9 (fr)	2003-12-18	Normalisation de la reactivite de lymphocytes t deficients par la manipulation de la regeneration thymique
US20020086003A1 (en)	2002-07-04	Stimulation of thymus for vaccination development
AU2002223106A1 (en)	2002-04-22	Stimulation of thymus for vaccination development
AU2002216320C1 (en)	2008-04-03	Hematopoietic stem cell gene therapy
AU2007202610A1 (en)	2007-06-28	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040037816A1 (en)	2004-02-26	Graft acceptance through manipulation of thymic regeneration
AU2007202609A1 (en)	2007-06-28	Stimulation of thymus for vaccination development
ZA200303684B (en)	2005-05-25	Stimulation of thymus for vaccination development
AU2002225245A1 (en)	2002-06-27	Improvement of graft acceptance through manipulation of thymic regeneration
US20020110540A1 (en)	2002-08-15	Disease prevention by reactivation of the thymus
AU2002216323A1 (en)	2002-06-27	Disease prevention by reactivation of the thymus
US20040037817A1 (en)	2004-02-26	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AU2002216320A1 (en)	2002-06-27	Hematopoietic stem cell gene therapy
ZA200303685B (en)	2004-08-13	Hematopoietic stem cell gene therapy.

Legal Events

Date	Code	Title	Description
2007-07-05	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted